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ABSTRACT 
 
Background: Selecting optimal aerosol device and interface of noninvasive ventilation (NIV) to 
children is a challenge.  The purpose of this study is to measure the delivery efficiency of two 
nebulizers with three interfaces in a simulated spontaneously breathing pediatric lung model. 
Methods: A ventilator (Trilogy 202, Philips) with single limb circuit (S/T mode, inspiratory 
pressure:  18 cmH2O, expiratory pressure: 8 cmH2O, respiratory rate: 30 and I:E ratio 1:2) was 
connected to a pediatric upper airway manikin via the standard oronasal mask (AF 541, 
Respironics), the oronasal mask with nose cushion (AF541, Respironics), and the nasal mask 
(PN 831 Respironics). A collecting filter was placed between the bronchi and a passive test lung 
(QuickLung, Ingmar Medical) with compliance of 20 mL/cmH2O and resistance of 20 
cmH2O/L/s. Albuterol sulfate (2.5mg/3 ml) was administered with jet (Micro Mist, Hudson RCI, 
Temecula, CA) and mesh (Aerogen Solo, Aerogen Ltd, Galway, Ireland) nebulizers during 
noninvasive ventilation (n=5).  Drug was eluted from filters and analyzed with 
spectrophotometry (276 nm). Descriptive statistics, Kruskal Wallis one way analysis of variance, 
and Mann Whitney U test were used for data analysis (p<0.05). Results: The result shows 
inhaled mass and inhaled dose % delivered (mean±SD) distal to the trachea.  The mesh nebulizer 
delivered significantly greater drug deposition than the jet nebulizer with the standard oronasal 
mask (p=0.0001), the oronasal mask with nose cushion (p=0.0001), and nasal mask (p=0.047). 
Aerosol deposition with the standard oronasal mask was greater than the oronasal mask with 
nose cushion and the nasal mask using both jet and mesh nebulizers. Conclusion: Type of 
nebulizer and masks had an impact on aerosol drug delivery to this simulated passive pediatric 
lung model receiving noninvasive ventilation. Both oronasal masks were more efficient than the 
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nasal mask by 15 – 20 fold, with either type of nebulizer.  The Mesh delivered 2-3 folder more 
drug distal to the tracheal than the Jet Nebulizer. 
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CHAPTER I 
INTRODUCTION 
 
 
             Aerosol therapy plays an essential role in the management of respiratory diseases. It is an 
effective way to deliver aerosolized medications to patients who suffer from pulmonary diseases, 
and one of it is advantages is that it can deliver smaller doses of medication directly to the lungs. 
Aerosolized medications are generally administered through several devices such as Jet 
Nebulizer (JN) and Vibrating Mesh Nebulizer, and different interfaces such as nasal mask and 
oronasal mask which can be used in children of all ages.  
 
In some situations, health care providers need to deliver aerosol therapy to pediatric 
patients receiving noninvasive ventilation (NIV). The presence of delivery interfaces as nasal 
mask or oronasal mask will interrupt the path of medication particles, which may affect the 
deposition of inhaled aerosol’s medications in the lung. The pediatric population ranges in age, 
which means patients present with different airway sizes, breathing patterns, and cooperation 
levels (Schüepp, Straub, Möller, & Wildhaber, 2004). These patient related characteristics 
influence the delivery and deposition of aerosolized medications in the lung. Therefore, the 
selection of the perfect device and interface to use to deliver aerosolized medications in line with 
NIV in a pediatric patient is a challenge.       
              Choosing the optimum device and interface is crucial in aerosol medication delivery via 
NIV. The proper choice will help health care providers make better choices. Previous studies 
showed that the Vibrating Mesh Nebulizer is superior to the Jet Nebulizer in medication 
delivery, but little is known about which interface yields greater medication delivery via NIV. 
Health care providers need more information about the optimum delivery interface to deliver 
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aerosolized medication in pediatric patients receiving NIV. In this study, the purpose is to 
measure the delivery efficiency of different aerosol devices, and interfaces that are used with 
pediatric patients who receive NIV. This is a basic experimental research where authors 
hypothesize that there is an impact on how aerosol therapy is delivered to patients in treatment 
deposition.  
 
The main question that will drive this research is: 
- What is the most efficient delivery interface to deliver aerosolized medication via NIV in 
a simulated pediatric lung model receiving NIV?  
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CHAPTER II 
LITERATURE REVIEW 
This literature review presents articles focused on the delivery of aerosolized medications 
in children receiving noninvasive ventilation. The articles in this study were collected from the 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Science Direct, Web of 
Science, and PubMed databases using the following terms: Children, aerosol, nebulizer, 
noninvasive ventilation (NIV), high flow nasal cannula (HFNC), breath-enhanced nebulizer, jet 
nebulizer, and vibrating mesh nebulizer. Relevant articles are divided into three categories: (1) 
aerosol drug delivery through NIV versus nebulization alone, (2) different type of interfaces, and 
(3) aerosol deposition with different devices. 
 
Aerosol Drug Delivery Through NIV versus Nebulization Alone 
Many researchers have tried to investigate a good way to deliver aerosolized medications   
into the lungs of patients receiving NIV. Pollack et al. (1995) used peak expiratory flow rate 
(PEFR) as a measurement tool to see how much patients improved after received aerosol 
therapy. In this study, they looked for the most effective way to deliver inhaled β-adrenergic 
agonist in acute bronchospasm either by delivering aerosolized medications during nasal positive 
airway pressure (BiPAP) or using small-volume nebulizer (SVN) alone without BiPAP. Patients’ 
age included in this study ranged from 18 to 40 years of age. All patients were admitted to the 
emergency room with acute bronchospasm and a history of asthma. Before delivering aerosol 
therapy, researchers measured oxygen saturation of arterial blood, pulse,  
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respiratory rate, and PEFR. Patients were randomly assigned into two groups. The first group of 
40 patients received two aerosol therapies with 2.5 mg albuterol in 3 mL normal saline by small-
volume nebulizer (SVN) and the second group of 60 patients had two therapies by BiPAP 
through a nose mask or face mask. The authors reported an improvement in PEFR from 211±89 
to 357±108 L/minute after the second treatment in the first group of patients as opposed to 
patients who received the treatment by SVN alone and whose PEFR improved from 183± 60 to 
280±87 L/minute (p = 0.0001). However, the pulse, oxygen saturation, and respiratory rate 
improved in similar ranges between the two groups.    
 Fauroux et al. (2000) evaluated the efficacy of pressure support ventilation (PSV) in 
improving aerosol deposition within the lungs of children with cystic fibrosis using in vitro and 
in vivo studies. In the in vitro study, the nebulizer alone was used as a control group and PS 
group received aerosols with a nebulizer through PSV. A different action triggered the nebulizer 
in the study. In the control group, the nebulizer was triggered by the inspiratory flow of the 
patient as opposed to the PSV group, in which nebulization was initiated by the positive pressure 
generated by PS ventilator. The solution used in the nebulizer was 2.5% KCI, and aerosol 
medication was captured by the filter attached to the carina. The PS ventilator was connected to a 
two chamber test lung, one was connected to a test lung, and another chamber was connected to 
the ventilator. The compliance of the test lung was at 50 mL/cm H2O with a resistance of 17 cm 
H2O at 1 L/s. Ventilator settings used in this study are RR of 20 breaths/minute, Ti of 1 second, 
inspiratory flow rate of 10 L/min, inspiratory trigger at -0.7 cm H2O, inspiratory pressure of 8 to 
10 cm H2O, and exhalation at 30% of peak inspiratory flow. The authors reported that the mass 
KCl was greater in the filter of the PS group than in the control group, but the results were not 
statistically significant. Also, they calculated the ratio of the amount of KCl by the number of 
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inhalations and the amount of KCl in the capture filter.  Both system ratios were stable from 50 
to 400 inhalations, and was 75% and 70% for PSV group and the control group, respectively.  
The in vivo study was on 18 children with cystic fibrosis aged 12±4 years with a vital capacity 
(VC) of 77±21% and a forced expiratory volume in 1 second (FEV1) of 72 ±26%. Every child 
received aerosol therapy with both SVN alone and PSV via nasal mask. The study shows aerosol 
deposition in the lung was 30% greater when using aerosol therapy with PSV than with SVN via 
a perfusion scan. Also, Fauroux et al. reported no relationship between aerosol deposition in the 
lung and age or height of the patients. But there was an inverse relationship between aerosol 
deposition and the percent predicted FEV1 in control and PSV groups (p=0.0025 and p<0.0001, 
respectively). The findings show that reduced lung function (measured by FEV1) had more 
asymmetric and more heterogeneous aerosol distribution.     
 Dai and colleagues (2014) examined the effect of different types of the exhalation valves 
(single-arch exhalation port, plateau exhalation valve, and whisper swivel) and the different 
positions of the nebulizer in the ventilator circuit such as proximal position (near the ventilator 
outlet) and distal position (between exhalation valve and lung model). In this study, the authors 
used a Michigan dual-chamber test lung and lung compliance was set to 0.05 L/ cm H 2O with an 
airway resistance of 4.3 cm H2O L-1 sec-1 at a flow rate of 60 L/minute. NIV was connected to 
the test chamber without a humidifier. The ventilator settings included VT of 500 mL, flow rate 
of 50 L/min, waveform is square-wave, RR of 20 breaths/min, and pressure rising slope of 3. The 
inspiratory and expiratory pressures were set at different levels (15/5, 15/10,25/5 and 25/10 cm 
H2O). 1 mL of 0.5% albuterol in 3 mL of normal saline was nebulized with the jet nebulizer.  
The aerosol was measured by spectrophotometry at 276 nm. Authors found an increase in the 
amount of the air leak with the single-arch exhalation port from 13.85 ± 0.32 L/min to 
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28.93±0.75 L/min as inspiratory pressure increased. However, the amount of air leak with 
plateau exhalation valve was constant at different pressure levels (24.01±0.68 L/min). Findings 
suggest that the single-arch exhalation port had the best aerosol delivery compared to any of the 
exhalation valves tested in this study when the nebulizer was placed distally (p<0.05), and had 
the lowest efficiency at proximal location (p<0.05). However, aerosol delivery at the proximal 
location was better than at the distal location when used with a plateau exhalation valve or 
whisper swivel. In addition, a direct relationship was found between inspiratory pressure and 
aerosol delivery (p<0.05) but the expiratory pressure was difficult to calculate.                
White et al. (2013) looked at how aerosol delivery through NIV was affected by different 
positions of exhalation leak valves in the ventilator circuit in the pediatric population. In this 
study, researchers used a pediatric resuscitation manikin (5.5 mm inner diameter ETT and lung 
model of a child with severe static asthmatics; a compliance of 20 mL/ cm H2O, resistance of 15 
cm H2O/L/s, and expiratory muscle of 5 cm H2O) connected to NIV. They used two bacterial 
filters in the lung model; one filter was used to capture aerosols and another filter was used to 
protect the lung model. NIV was attached to a heated wire circuit and the settings were BiPAP 
S/T mode with an inspiratory pressure of 16 cm H2O, expiratory pressure of 8 cm H2O, FiO2 
0.50, rise time of 2 second, and Autotrack trigger.  Albuterol (5 mg with 2.5 mL of the normal 
saline) was delivered by mesh nebulizers (Areoneb solo) set at three different positions in the 
circuit: before the humidifier and leak valve; between the humidifier and leak valve; and 
integrated within the mask and after the leak. Albuterol was measured by HPLC and detector 
wavelength (278 nm). The researchers reported that there was more albuterol delivered on 
pediatric NIV when the vibrating-mesh nebulizer was combined into the mask than any other 
positions (p<0.001). When the nebulizer was placed prior to the exhalation leak valve, grreater 
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aerosol delivery was noted than the nebulizer position between the humidifier and the leak valve 
(p=0.002).      
In a crossover clinical trial, Galindo-Filho et al. (2015) used mesh and jet nebulizers during 
NIV to compare radio-aerosol pulmonary index, and radio-aerosol mass in pulmonary and extra 
pulmonary settings. The study included 10 healthy adults (between 18 and 60 years of age) who 
were assigned to two groups.  The first group of 10 subjects received aerosol therapy by the jet 
nebulizer and the second group received aerosol by the mesh nebulizer. Both groups received 2.5 
mg of salbutamol, 0.25 mg of ipratropium bromide with 3 mL of technetium-99m 
diethylenetriaminpedntaacetic acid, and 0.9% saline solution via nebulizer during NIV 
(inspiratory pressure of 5 cm H2O and expiratory pressure of 12 cm H2O) with a facemask.  
After inhalation, researchers used the gamma camera to measure radio-aerosol. Authors reported 
that the mesh nebulizer produced >2-fold more aerosols than the jet nebulizer (972.013±214.459 
vs.386.025±130.363, p=0.005).    
 Michotte and colleagues (2014) analyzed inhaled and exhaled doses of three types of 
nebulizers (mesh, jet, and ultrasonic nebulizers) combined with bi-level ventilator.  They 
assessed the effect of nebulizer placement on these doses. The test lung had two chambers.  The 
first chamber was aping the adult respiratory muscles with obstructive disease (VT=400 mL, 
RR=15 breaths/min, I/E ratio=1:3, inspiratory time=5% of respiratory cycle) and attached to a 
ventilator. The second chamber was mimicking the lung and attached the bi-level ventilator 
(BiPAP). The ventilator settings included PS mode with inspiratory pressure of 20 cm H2O, 
expiratory pressure of 5 cm H2O, flow trigger of 9 L.m-1, inspiratory rise time at level 1, and 
inspiratory cycle-off 30%. The authors tested each nebulizer at two different positions, before 
and after the exhalation port in an adult lung model receiving NIV. They measured the inhaled 
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dose, the exhaled dose, and the total lost dose by using the residual gravimetric method. The 
results from the study showed a benefit for the use of the mesh nebulizer before the exhalation 
valve (p<0.001). This position demonstrated the greatest deposition of medication. The mesh 
nebulizer delivered the highest inhaled dose compared to other nebulizers tested in this study. 
The placement of the mesh nebulizer after the exhalation port delivered the highest inhaled 
(p<0.001) and expiratory wasted dose (p<0.001). The jet nebulizer had highest exhaled dose 
when it is placed before the exhalation valve (p<0.001). The ultrasonic nebulizer is not 
recommended because of its maximum total lost dose compared with mesh and jet nebulizers 
(p<0.001).  
Calvert et al. (2006), evaluated the delivery of nebulized aerosol during non-invasive 
ventilation by using a lung model simulating COPD adult respiration. The breathing simulator 
was set with a VT of 600 mL, RR of 12 breaths/min, and Ti of 40%.  The bi-level ventilator was 
set in spontaneous mode at an inspiratory pressure (IPAP) of 20cmH2O and expiratory pressure 
(EPAP) of 5cmH2O. The nebulizer alone was used as a control group and NIV group received 
aerosols with a nebulizer through NIV. Nebulizer solution was Salbutamol 5mg in 2.5 mL 
normal saline using jet nebulizer. The nebulizer location was different within the ventilator 
circuit. The spaces between the nebulizer and the breathing simulator were 10cm, 19cm, and 
204cm for locations A, B, and C, respectively. In the control study, the nebulizer was connected 
straight to the facemask via a T-piece without NIV. The aerosol was measured by 
spectrophotometry at 276 nm. There was significant output of salbutamol to the filter when 
placing the nebulizer at position B in the circuit (P > 0.05) than position A (544 ± 85 mg) or 
position C (267 ± 26 mg) (P < 0.001). Also, the nebulizer at position B was significantly better 
than nebulization without the ventilator (424 ± 61 mg; p < 0.01). 
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Abdelrahima et al. (2010), examined effective ventilation during Non-invasive 
ventilation (NIV) with nebulized bronchodilators in chronic obstructive pulmonary disease.  In 
this study, a breathing simulator was used  and the settings were a VT of 500 mL, RR of 15 
breaths per minute, and I: E ratio of 1:3. The bi-level ventilator was set in spontaneous mode at 
an inspiratory pressure of 20 cm H2O and expiratory pressure of 5 cm H2O. Authors used the 
Aeroneb Professional (AERO) and the Sidestream (SIDE) nebulizer. AERO is a vibrating mesh 
nebulizer and SIDE is a jet nebulizer. Nebulizer solution was two mL of 5 mg of terbutaline 
sulfate respiratory solution (Bricanyl Respules containing a nominal dose of 2.5 mg/mL; 
AstraZeneca, UK). They used three electrostatic filters. The first electrostatic filter was used as 
an inhalation filter which connected to a breathing machine to measure the total inhaled aerosol 
dose. The second electrostatic filter was used as a ventilator filter which connected to a ventilator 
to check if aerosol reaches the ventilator. The third electrostatic filter was used as an expiration 
filter which was connected 4 cm above the outlet of the expiration port of the NIV system. A 
vacuum of 25 l/min was drawn through the circuit which ensured the capture of the entire dose 
that was expelled from the NIV system. The nebulizers were tested on two positions; in position 
A, the nebulizer was direct to the breathing simulator and in position B, the expiration port was 
direct to the breathing simulator. The researchers reported higher concentration of terbutaline on 
the inhalation filter than the expiration port in position A	than in position B (p<0.001) for both 
nebulizers. The mesh nebulizer on positions A was captured leaving the expiration port than was 
entrained on the inhalation filter (p<0.001). The jet nebulizer on positions A and B was captured 
leaving the expiration port than was entrained on the inhalation filter (p<0.001). There were 
similarities of residual volumes left in the chambers for mesh nebulizer in both positions, as well 
as jet nebulizer in both positions.  
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In a prospective randomized controlled study, Brandão et al. (2009) assessed the effect of 
jet nebulization administered to spontaneous breathing patients, suffering an acute asthmatic 
episode.on NIV. They select 36 patients (18-65 years) diagnosed with severe asthma. Criteria for 
inclusion were patients with an FEV1 less than 60% of predicted, history of asthma for at least 
one year, and present asthma catastrophe lasting less than 7 days. Criteria for exclusion were if 
patients smoked, used anti-inflammatory drugs, had chronic obstructive pulmonary disease, were 
hemodynamically unstable (defined as having a heart rate over 150 bpm or systolic pressure 
below 90 mmHg), had congestive heart failure, altered consciousness, facial deformity, or were 
pregnant. Patients were randomized into three groups: control group (nebulization alone), 
experimental group 1 (nebulization and NIV with inspiratory positive airway pressure [IPAP] = 
15 cm H2O and expiratory positive airway pressure [EPAP] = 5 cmH2O), and experimental 
group 2 (nebulization and NIV with IPAP= 15 cm H2O and EPAP = 10 cm H2O). The 
nebulization solution was 2.5 mg of fenoterol bromidrate, 0.25 mg of ipratropium bromide, and 4 
mL of physiological saline (NaCl at 0.9%). Aerosol was administered with a jet nebulizer for all 
three groups. The researchers recorded respiratory rate (RR), heart rate (HR), oxygen saturation 
(SpO2), peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital 
capacity (FVC), and forced expiratory flow between 25% and 75% (FEF25−75). Data was 
collected before and after 30 minutes of each intervention. The authors reported that the RR 
lower (p = 0.04) 30 minutes after treatment compared with before treatment with Experimental 
group 1. No changes were witnessed for either HR or SpO2. There was no difference in HR, RR, 
and SpO2 collected 30 minutes after treatment compared with before treatment between the 
control group and experimental group 2. There was significant higher PEF (p < 0.03), FVC (p < 
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0.03), FEV1 (p < 0.03), and FEF25−75% (p < 0.00) in experimental group 2, however for 
experimental group 1, just the PEF (p <0.04) was higher.  
 Françaa et al. (2005) assessed pulmonary radioaerosol deposition during jet nebulization 
with noninvasive ventilation against spontaneous breathing nebulization (SB). The study was 
done in 13 healthy volunteers (nine females and four males) with normal spirometry. Their age 
was 23.4 ±1.49 (SD) years and body mass index (BMI) was 21.2±2.3 kg/m2. Criteria for 
exclusion were if patients smoked or have respiratory problems, pregnancy, breathing rate >20 
bpm, heart rate <50 or >100 bpm, oxygen saturation (SpO2) ≤ 90%, maximal inspiratory 
pressure ≤ 50 cm H2O, Vt ≤ 6 mL/kg, forced vital capacity (FVC) < 81%, and forced expiratory 
volume on the 1 s (FEV1) < 82% of predicted values. All volunteers underwent nebulization in 
two phases, one in SB and another with bi-level NV. There were 7 days of washout period 
between two phases. The nebulization solution was technetium (Tc99m) and diethylene triamine 
penta acetic acid, produced by a jet nebulizer. After the radioaerosol radioactive inhalation, the 
volunteers stayed in the scintigraphy camera. Authors observed that pulmonary deposition of 
radioaerosol when connected to bi-level NIV was less when compared to SB (p<0:001). There 
was lower significance of radioaerosol deposition in upper, middle, and lower thirds of the lung 
when nebulization was carried out connected to bi-level NIV than with SB nebulization 
(p<0:001). There was a significant relationship between Vt and radioaerosol deposition (r.= 
0.565, p< 0:05) in spontaneous breathing nebulization, and between inspiratory flow and 
radioaerosol deposition in the lungs (r =0.141, p< 0:05). During bi-level NIV nebulization, there 
was no relationship between Vt and pulmonary deposition of radioaerosol (r = 0.082). 
Mukhopadhyay et al. (2009) assessed the effects of disconnecting noninvasive ventilation 
(NIV) used during acute exacerbation of chronic obstructive pulmonary disease for the delivery 
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of aerosolized medications on physiologic factors and dyspnea sensation. The study was done in 
19 patients. Criteria for inclusion were patients with COPD (2) requiring NIV for type 2 
respiratory failure with pH of 7.25 to 7.35 and raised PaCO2 while maintaining oxygen 
saturation between 88% and 92%; (3) mentally alert and able to answer simple questions on 
breathlessness. Criteria for exclusion were if pneumonia was noticed by chest radiography, they 
were hemodynamically unstable, or unable to answer questions because of drowsiness or 
disorientation. All volunteers underwent 4 phases in this study; NIV1 phase, oxygenation phase, 
nebulization phase, and NIV2 phase. NIV1 phases. Patients were placed on NIV for 10 minutes 
and ventilation settings were peak inspiratory pressure 19 (±4) cm H2O, PEEP 4 (±1.5) cm H2O, 
and FiO2 32% ±6%. Before the removal NIV, researcher recorded the following parameters: 
peak inspiratory pressure, positive end-expiratory pressure (PEEP), tidal volume (Vt), respiratory 
rate (RR), fractional concentration of inspired oxygen (FiO2), oxygen saturation (SpO2), heart 
rate (HR), and blood pressure (BP). The subjects were then asked questions in the language of 
their best understanding (English, Malay, or Mandarin) to indicate their level of breathlessness 
on the modified Borg score. A clinician then indicated by “yes” or “no” whether the subject was 
using accessory muscles to breathe. Finally, an ABG sample was drawn and analyzed. In the 
oxygenation phases, the patients were removed from the NIV and put on oxygen via nasal 
cannula to maintain an oxygen saturation of 88% to 92%. This phase helped to avoid overlapping 
effects of NIV and nebulization on physiologic parameters. After 10-minute oxygen therapy, the 
vital signs, accessory muscles usage, and the Borg score were again recorded. In the nebulization 
phases, the patients received bronchodilator nebulization treatment with salbutamol 5 mg and 
ipratropium 500 µg administered via small volume nebulizer. Following the end of the nebulizer 
treatment, the vital signs, the Borg score, and use of accessory muscles were again recorded. 
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Finally, ABG sample was drawn and analyzed. In the NIV2 phase, the patients were then put 
back on NIV with the same ventilation settings. After 10 minutes, the vital signs, accessory 
muscles usage, and the Borg score were again recorded. Authors reported there were no 
significance different between two phases of NIV in all parameters. Between NIV and 
nebulization phases there were no significant changes in physiologic parameters and 
oxygenation. Only physiologic changes were seen and the result show an increase in systolic BP 
(SBP, p = .012) and HR (p = .003) after nebulization. More patients were assessed to be using 
the accessory muscles of respiration after discontinuation of NIV (22% vs. 44%, P = NS). There 
was a significant decrease in oxygen saturation (P = .009) and increase in SBP (P = 
nonsignificant) between NIV and oxygenation phases. 
In a prospective study, Nava et al. (2001) examined clinical response of salbutamol 
delivered through metered dose inhaler (MDI) during noninvasive mechanical ventilation 
(NIMV-MDI), during spontaneous breathing using a spacer (MDI-Spacer), and during 
intermittent positive pressure ventilation (IPPB). They selected 18 patients (age < 75 years) 
diagnosed with COPD. Criteria for inclusion were patients with an FEV1/FVC less than 60%, 
and FEV1 < 1.5 or 50% predicted. Another criteria were patient who used short- or long- acting 
ß2-agonist as chronic therapy.  Arterial blood gas sampling, pulmonary function test, and vital 
signs were recorded. This study has two sets of experiments. The first set of experiments has 10 
patients. Before the start of the study, all medication except oxygen were stopped at least 24 h. 
The study was conducted on four consecutive days. 1) placebo via spacer chamber; 2) 400 mg 
dose of salbutamol via MDI-Spacer; 3) 400 mg dose of salbutamol via NIMV-MDI, and 4) 5 mL 
of saline solution with 5 mg of salbutamol via IPPB. Authors measured FEV1 prior to the test to 
checked the patients’ clinical stability. During NIMV, ventilation setting was volume-assured 
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pressure support; pressure support 14.3 ± 1.8 cmH2O and VT guarantee of 10 mL/kg. The 
inspiratory trigger was set at -0.5 cmH2O. All patients were breathing room air and used a full-
face mask. During IPPB, the setting was a pressure of 15 cmH2O, a flow rate of 50 l/m, and no 
oxygen supplementation. All the measurements were recorded 10 min before the start of aerosol 
therapy and then repeated 15 min and 30 min after aerosol therapy. The second set of 
experiments had 8 patients. The study was conducted on two consecutive days. 1) 400 mg of 
salbutamol via NIMV-MDI, 2) placebo via NIMV-MDI. The ventilator setting as described 
above. Authors report that there was a significant improvement in FEV1 salbutamol compared to 
placebo. ∆ FVC significantly increased with NIMV-MDI. In the second set of the experiment, 
the researchers found improvements in FVC in both trials (placebo or salbutamol via NIMV-
MDI) (+206 ± 147 mL and 208 ±145, respectively). However, there was a significant increase in 
FEV1 after salbutamol. 
Reychler et al. (2007) evaluated lung deposition of amikacin produced by jet nebulizer 
(SideStream) used alone (SST) or combined with a CPAP machine. They recruited six non-
smoking healthy male volunteers with a normal lung function. Their mean age = 27.3 ± 2.2; 
height = 179± 3 cm; and weight = 77± 4 kg. All volunteers underwent nebulization in two 
phases, one in (SST) and another in connection to CPAP. There was one week of washout period 
between each nebulization. The solution was amikacin sulfate dissolved in 4 mL 0.9% NaCl 
solution to a concentration of 250 mg mL-1. The CPAP setting was 6 cm H2O.  The researchers 
requested the urine sample to be collected before nebulization and after 24 h from therapy. They 
assessed urinary amikacin concentration by fluorescent polarization immunoassay. Also, they 
measured residual volume by pipetting after a 5-minute rest period. Authors reported that the 
amount of amikacin excreted in the urine was 2.5-fold lower with CPAP than with SST. There 
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was significantly higher level of amikacin excreted in the urine with SST than with CPAP 
(4.88% initial dose versus 1.97% initial dose, p<0.001). The residual amount of amikacin in the 
nebulizer was lower with SST than with CPAP (541 mg versus 607 mg), but the results were not 
significant (p = 0.35). 
In a laboratory study, Chatmongkolchart (2002) studied the effect of ventilator 
parameters and nebulizer position on aerosol delivery during NIV.  In this study, the authors 
used a Michigan adult dual-chamber test lung and lung compliance was set to 0.064 L/ cm H 2O 
with an airway resistance of 4.3 cm H2O L-1 sec-1 at a flow rate of 60 L/minute. NIV was 
connected to the test chamber without a humidifier. The ventilator settings (BiPAP S/T) included 
a flow rate of 25% duty cycle, the waveform is sinusoidal-wave, and RR of 10 and 20 
breaths/minin. The inspiratory and expiratory pressures were set at different levels (10/5,15/5, 
20/5, 15/10, 20/10, and 25/10 cm H2O). One mL of 0.5% albuterol in 3 mL of normal saline was 
nebulized with the jet nebulizer. The nebulizer was placed in either a proximal (ventilator outlet) 
or distal position (between circuit leak and the collecting filter). The aerosol was gathered by 
filter located at the inlet of lung model. Authors found an increase in the amount of the aerosol 
delivery with nebulizer placed at the distal position and RR of 20 breaths/ min. There was a 
significant effect in aerosol deposition by nebulizer position, RR, and the BiPAP setting 
(p<0.001). Furthermore, there was a significant effect between RR and the BiPAP setting 
(p<0.001), nebulizer position and the BiPAP setting (p<0.001), and nebulizer position and RR 
(p<0.001).  
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Different Type of Interface  
Clinicians should select the most appropriate interface for NIV for the best clinical outcome. 
Ramirez et al. (2011) evaluated the best interface for long-term NIV in children. The study was 
done in 97 children with neuromuscular or thoracic scoliosis (35 patients), obstructive sleep 
apnea (32 patients), maxillofacial deformity (21 patients), and lung disease (9 patients).  The 
author selected the interface based on age, disease, patient tolerance, absence of skin injury, pain, 
and leak. During the study, authors changed the interface due to discomfort (16 patients), leaks 
(4 patients), facial growth (3 patients), skin injury (2 patients), and changes in the ventilator 
mode (2 patients). The result was 50% of children fitted to the nasal mask, 16% to face mask, 
and 2% to nasal prongs. Noise during NIV is considered one of the important factors of 
cooperative patients with NIV. 
Cavaliere and colleagues (2004) assessed noise during NIV with three types of interfaces 
(helmet, nasal, and face mask) in 10 heathy adults (23-49 y). They received NIV at a pressure 
support of 10 and 15 cm H2O. The three masks were tested randomly, and each test took 15 
minutes to complete. They measured sound by putting the microphone close to the right ear. The 
result was helmet noise registered more than 100dB, but nasal and facial masks did not exceed 
70dB.  
Urbüz et al. (2015) compared helmet with face mask in 50 COPD patients receiving NIV. 
Participants of the study were divided into two groups. The first group of 25 patients used the 
helmet while the second group of 25 patients were connected to NIV with the face mask. 
Settings of NIV included FiO2 0.40, PEEP 5-7 cm H2O, PS 10 cm H2O, and trigger -2 cm H2O.  
Authors measured demographic data, FEV1, hemodynamics, vital signs, arterial blood gases, and 
FiO2 before starting the test. Then, they documented these parameters in 30 min intervals of NIV 
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until 120 min, 24 h, and 48 h. Researchers reported that there was no difference between the two 
groups based on the parameters measured in this study (p>0.05) except the CO2 that decreased 
with the full-face mask compared to the helmet. 
   Branconnier et al. (2005) tested delivery efficiency of different aerosol devices such as 
the nebulizer or the metered-dose inhaler (MDI) by using two different types of masks during 
NIV. The Spectrum mask that has the leak port in the circuit and Mirage mask with the leak port 
in the mask were tested in this study. They used a lung model connected to the ventilator (BiPAP 
mode) with 15/5 cmH2O, RR 20 breaths/minute, and tidal volume 0.4 L. The amount of aerosol 
captured on the filter was analyzed from the absorption-concentration and the stander, and then 
measured with the spectrophotometer using a 1mL quartz cuvette at the wavelength of 276 nm. 
The results of this study showed that the nebulizer delivered more albuterol than the MDI 
(p<0.01). There was significantly more albuterol delivered with the Spectrum mask (p=0.001). 
Delivery efficiency of the nebulizer and MDI was similar with the Spectrum mask (p=0.57), 
while albuterol delivery was better on MDI with the Mirage mask (p=0.001).  
   Lin et al. (2012) studied the impact of nebulizer types and different aerosol masks on 
drug deposition in pediatrics by using a lung simulator with settings for a spontaneously 
breathing child (2-4 years old). The study set a tidal volume of 150 mL, inspiratory time 0.8 sec, 
flow rate 20 l/min, and RR 25 breaths/min. They used three different types of nebulizers 
(constant-output, breath-enhanced, and breath actuated nebulizers) and three types of masks 
(standart face mask, Fish mask, and valved mask). The inhaled aerosol was salbutamol sulfate 
(5.0 mg/2.5 mL with distilled water). The total nebulizer fill volume of 4 mL was used in this 
study. The amount of aerosol was collected by the filter placed distal to the trachea. Inhaled dose 
was measured via spectrophotometry at 276 nm. The nebulization time of each nebulizer was 
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measured. The result showed that the breath actuated nebulizer had lower aerosol deposition and 
longer treatment times compared to other nebulizers (p=0.001). Constant aerosol generation had 
the highest aerosol deposition and shortest times of nebulization (p=0.025). The Fish mask had 
higher aerosol deposition than the others (p=0.001).  
 
Aerosol Deposition with Different Devices 
Ari et al. (2015) evaluated the efficiency of mesh nebulizer (MN) with proprietary adapter 
and a jet nebulizer (JN) using different interfaces in adult and pediatric models. In this study, the 
authors used adult and pediatric models attached to a sinusoidal pump via a collecting filter at a 
level of the bronchi. A spontaneously breathing adult settings (TV of 500 mL, RR of 15 
breaths/min and I: E ratio of 1:2) and a spontaneously breathing Pediatric settings (TV of 150 
mL, RR of 25 breaths/min and I: E ratio of 1:2) were used. The adult interfaces tested in this 
study included the mouthpiece, the aerosol mask, and the valve-mask. The pediatric interfaces 
tested were the dragon mask, the aerosol mask, and the valve-mask. Albuterol sulfate (2.5 mg/3 
mL) was collected in the filter and analyzed by spectrophotometry. The researchers reported that 
the delivery efficiency of JN was two-fold less than MN when a mouthpiece or valve –mask was 
used for aerosol therapy using the adult lung model (p=0.013 and p=0.014, respectively). 
However, drug delivery by an aerosol mask with MN was less efficient than the mouthpiece or 
valve-mask (p=0.0 001 and p=0.0001, respectively). There was no significant difference in an 
aerosol deposition by using mouthpiece or valve-mask with JN and MN (p=0.0 121 and p=0.951, 
respectively). The inhaled dose with adult lung model was greater than a pediatric model with 
both JN and MN (p<0.05). Also, aerosol deposition was significantly greater in an adult lung 
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model than the infant lung model used with JN (p=0.001 and p=0.002, respectively) and MN 
(p=0.001 and p=0.005, respectively).  
Pitance et el. (2010) evaluated the efficacy of a mesh nebulizer and a jet nebulizer by 
measuring inhaled mass and urinary drug concentration of amikacin using in vitro and in vivo 
studies. Authors used three different nebulizer delivery structures: jet nebulizer alone, jet 
nebulizer with 110 mL corrugated tube, and a vibrating mesh nebulizer. In the in vitro study, 
they used adult lung model set at RR of 20 breath/min, VT of 440 mL, 10% inspiratory pause, 
and 33% I/E ratio. Every nebulizer was filled with 4 mL of amikacin (125 mg/mL) and was 
weighted unfilled when filling, and at the end of nebulization. The in vivo study was on six non-
smoking healthy male aged 28±4.4 years. Volunteers were randomly selected to the three 
nebulizer configurations. Every volunteer received a single therapy from each nebulizer. There 
was 48 hours of washout period between each nebulization. The researchers requested the urine 
should be collected before nebulization and after 24 h from therapy. They assessed urinary 
amikacin concentration by fluorescent polarization immunoassay. They showed that the mesh 
nebulizer had higher inhaled mass than another device. The percentage of amikacin increased 
with corrugated tubing by 2-3 fold compared to without it. The jet nebulizer had significantly 
higher drug mass than two jet nebulizers (p<0.05). However, the amount of amikacin in the 
reservoir at the end of nebulization was significantly higher with two jet nebulizers than the 
mesh nebulizer (p<0.001). 
In a crossover clinic trial, Dugernier et al. (2016) compared a vibrating mesh nebulizer with a 
valved holding chamber and a conventional jet nebulizer with a corrugated tube for lung 
deposition. The study was performed on six healthy male subjects (18 or older), who were non-
smokers with no evidence of respiratory disease, and who had normal lung function tests. The 
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diethyleneteriaminepentaaccetic acid labeled with technetium-99 m was measured by single-
photon emission computed tomography combined with a low-dose CT-scan (SPECT-CT). Every 
volunteer received a single therapy from each nebulizer. There was 60 hours of washout period 
between each nebulization. Authors reported that aerosol delivery with the vibration mesh 
nebulizer was >6-times greater than the jet nebulizer (43.1±6.0% versus 5.2±1.1%, p<0.001).    
In conclusion, this literature review has shown that there are many factors affecting the 
aerosol delivery through a NIV, including the nebulizer types, interfaces, types and position of 
exhalation valve, tidal volume used, and pressure used in NIV. The most commonly used 
nebulizer devices with the NIV are jet and vibrating mesh nebulizer. Research shows that the 
mesh-nebulizer delivered the highest inhaled dose when used after the exhalation port. However, 
the jet nebulizer had the highest exhaled dose before the exhalation valve. The ultrasonic 
nebulizer is not recommended because of the maximum total lost dose compared with mesh and 
jet. Regarding interfaces, a nasal mask is generally superior than a face mask or nasal prongs. In 
terms of types of exhalation valve, the single-arch exhalation port had the best aerosol delivery 
than plateau exhalation valve or whisper swivel. The used of low Vt when administering aerosol 
with a nebulizer increases aerosol delivery. On the other hand, greater inspiratory pressure 
correlated with increased aerosol delivery. Finally, breathing patterns affect delivery, and aerosol 
delivery decreased in the pediatric population. 
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CHAPTER III 
Methods 
 
Research Design 
 This is an experimental study in which the delivery efficiency of different aerosol devices 
and interfaces that are used in children receiving NIV will be determined. The method of 
sampling will be non-probability purposive sampling based on literature review and commonly 
used interfaces and devices for aerosol drug delivery in clinical practice. 
Lung Model 
 This study will use a pediatric teaching mannequin and an in vitro lung model will be 
prepared to conduct this study. The upper airway of the teaching mannequin will be attached to a 
collecting filter at the level of bronchi connected to a passive single chamber test lung 
(QuickLung, IngMar Medical, Pittsburgh, USA) to represent the breathing parameters of a 5 
year-old child. The target tidal volume will be 180 mL, the respiratory rate will be 30 
breaths/min, and I:E ratio of 1:2 will be used. Both the tidal volume and leak will be monitored 
continuously during each experiment. A collecting filter (Respirgard II, Vital Signs, San 
Antonio, TX) will be placed between the bronchi of a pediatric upper airway manikin (child 
airway management trainer IF03609U, Nasco) and the test lung (QuickLung, Ingmar Medical) 
with compliance of 20 mL/cmH2O and resistance of 20 cmH2O/L/s. This filter will be used to 
collect the aerosolized drug. A vibrating mesh nebulizer (Aerogen Solo, Aerogen Ltd, Galway, 
Ireland) and jet nebulizer (Micro Mist, Hudson RCI, Temecula, CA) will be placed between the 
leak port and the interface that will be tested in this study. A ventilator (Trilogy 202, Philips) 
with single limb circuit (S/T mode, inspiratory pressure:  18 cmH2O, expiratory pressure: 8 
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cmH2O, respiratory rate: 30, and I:E ratio 1:2) will be connected to a pediatric upper airway 
manikin via mask.  
  
   
 Variables 
 Two independent variables will be examined in this research. The first independent 
variable is the interfaces, including the standard oronasal mask (AF 541, Respironics), the 
oronasal mask with nose cushion (AF541, Respironics), and the nasal mask (PN 831 
Respironics). The second independent variable is the nebulizer: (1) Jet Nebulizer (Micro Mist, 
Hudson RCI, Temecula, CA) and (2) Vibrating Mesh Nebulizer (Aerogen Solo, Aerogen Ltd, 
Galway, Ireland) (Alhamad, Fink, Harwood, Sheard, & Ari, 2015).  The measured dependent 
variable will be aerosol drug delivery distal to the trachea.  
 
Figure 2.  Experimental set-up of 
 the study using the mesh nebulizer 
Figure 1.  Experimental set-up of 
 the study using the jet nebulizer 
Figure 3.  Three interfaces tested: 
 (A) the standard oronasal mask, 
 (B) the oronasal mask with nose cushion,  
 (C) the nasal mask 
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Settings 
The study will be conducted in the Aerosol Research Laboratory in the Department of 
Respiratory Therapy at Georgia State University (GSU). 
Procedures 
 Albuterol sulfate (2.5mg/3 ml) will be administered with jet and mesh nebulizers during 
NIV. Oxygen flow of 8 L/min will be used to operate the jet nebulizer until sputter, while the 
drug solution will be aerosolized by the vibrating mesh nebulizer until no more aerosol is seen.  
The same experimental setup will be used in five nebulization sessions (n=5). After each session, 
albuterol sulfate deposited on the filter will be measured by rinsing the filter with 10 ml of 0.1 N 
hydrochloric acid (JT Baker Company, Phillipsburg, NJ) using a gentle stirring for 3 minutes to 
ensure proper mixing. A calibrated spectrophotometry device (Beckman Instruments, Fullerton, 
CA) will measure albuterol concentration in the solution. 
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Table 1.  Gantt Chart 
 
 
 
 
 
 
 
 
 
 
 
 
Task /Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
University permission 
and funding 
              
Contact Medical 
equip. the company 
              
Initiate experiments               
Data cleaning               
Analysis               
Data Recording               
Review               
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Data Collection 
As shown in Figure 4, a total of 30 runs, 15 using the vibrating mesh nebulizer and 15 using the 
jet nebulizer will be conducted with each interface (n=5). 
Figure 4.  A scheme of variables and experiments plan in the study 
 
Statistical Analysis 
 Variables conducted in this research are interfaces and nebulizers. As a result, the amount 
of albuterol sulfate deposited on the filter will be calculated as a percentage of the total inhaled 
drug mass delivered distal to trachea after each experiment. In comparison, significance is 
defined as a p value < 0.05. Analysis will be performed by a Statistical Package for the Social 
Sciences (IBM SPSS, 24.0).   
Data management and storage 
 Prior to data entry into a computer database (Microsoft Excel), a codebook will be 
created to describe each variable and how information will be entered. Data security will be 
Aerosol	Delivery	to	
Pediatrics	during	
NIV
Jet	Nebulizer
oronasal	mask	
with	nose	cushion
(n=5)
Nasal	Mask
(n=5)
stander	Oronasal	
Mask
(n=5)
Mesh	Nebulizer
oronasal	mask	
with	nose	cushion
(n=5)
Nasal	Mask
(n=5)
stander	Oronasal	
Mask
(n=5)
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ensured by protecting computer files with a password for restricted access and use. The Data 
Management Advisory Team (DMAT) in the university library will be available for assistance in 
managing the data. 
 
CHAPTER IV 
RESULTS 
This study compared the amount of aerosol delivered to the trachea (the inhaled mass) and 
the inhaled mass percentage of the three-aerosol mask (Standard Oro-nasal Mask, Oronasal 
Mask with Nose Cushion, and Nasal Mask) using both jet nebulizer and vibrating mesh 
nebulizer. 
 Table 2. presents the means (± standard deviation) of albuterol mass deposited on the inspiratory 
filter for each type of aerosol mask and percent of the nominal dose for (the standard oronasal 
mask, the oronasal mask with nose cushion, and the nasal mask) using the jet and vibrating mesh 
nebulizers. 
Table 2. Needs a title (n=5) 
 
 
 Mesh Nebulizer Jet Nebulizer 
 
Standard 
Oronasal 
Mask 
Oronasal Mask 
with Nose 
Cushion 
Nasal 
Mask 
Standard 
Oronasal 
Mask 
Oronasal Mask 
with Nose 
Cushion 
Nasal 
Mask 
 
Inhaled 
Mass 
(mcg) 
506.5 ± 61.9 437.6 ± 38.4 
 
52.2 ± 
29 
 
193.2 ± 
15.8 
 
135.2 ± 27.2 
 
21 ± 5.5 
 
Inhaled 
Dose % 
 
20.3 ± 2.5 
 
17.5 ± 1.5 
 
2.0 ± 1.1 
 
7.7 ± 0.6 
 
5.4 ± 1.1 
 
0.8 ± 0.2 
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The Effect of Aerosol Mask Type on Aerosol Drug Delivery 
Delivery of albuterol was greater with the standard oronasal mask using both mesh and jet 
nebulizers (20.3 ± 2.5% and 7.7 ± 0.6%, respectively) compared with the oronasal mask with 
nose cushion (17.5 ± 1.5% and 5.4 ± 1.1%, respectively). The nasal mask (2.0 ± 1.1% and 0.8 ± 
0.2%, respectively) had the lowest deposition. Both oronasal masks were more efficient than the 
nasal mask by 15–20 fold, with either type of nebulizer. 
 
 
The Effect of Nebulizer Type on Aerosol Drug Delivery 
The vibrating mesh nebulizer resulted 2–3 fold larger dose than the jet nebulizer in the mean 
inhaled percent of the dose delivered with all types of aerosol masks. The mesh nebulizer 
delivered significantly more drug deposition than the jet nebulizer with the standard oronasal 
mask (p=0.0001), the oronasal mask with nose cushion (p=0.0001), and the nasal mask 
(p=0.047). 
 
 
0
5
10
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20
25
Standard	Oronasal	Mask Oronasal	Mask	with	Nose	
Cushion
Nasal	Mask
Inhaled	Dose	%
Jet	Nebulizer Mesh	Nebulizer
Figure 6.  Comparison of jet 
nebulizer (dark bar) and mesh 
nebulizer (gray bar) inhaled 
mass percent (Mean – SD) for 
the stander oronasal mask, the 
oronasal mask with cushion 
and the nasal mask 
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CHAPTER V 
DISCUSSION 
 Pediatric patients on noninvasive ventilation could require aerosol therapy and in a 
relatively short period of time. Therefore, timely and efficient delivery of aerosol drugs should 
provide an essential medical role in decreasing airway obstruction, ventilator impairment, and 
respiratory distress. A study conducted by Nava et al. (2001), demonstrated superior aerosol drug 
delivery through noninvasive ventilation than without positive pressure. Fauroux et al. (2000), 
analysed pediatric patients with cystic fibrosis demonstrated 30% increase in aerosol drug 
delivery with the use of nebulization delivered with noninvasive ventilation than without 
noninvasive ventilation. Therefore, the use of aerosol delivery on noninvasive ventilation could 
increase aerosol drug delivery, and decrease work of breathing. 
 Dai. (2014), Michotte. (2014), Claver. (2006), Abdharh. (2010), Chatmongkolchart. 
(2002), 7 clinical studies Brandão. (2009), França. (2005), Mukhopadhyay. (2009), Nava. 
(2001), Pollack. (1995), Galindo-Filho. (2015), and Reychler. (2007), assessed aerosol drug 
delivery in adult noninvasive ventilation. Although there are numerous adult studies in this field, 
there are only two pediatric noninvasive ventilation studies. One in vitro study, White et al. 
(2013), was designed to assess the influence of different positions/exhalation leak valves on the 
ventilator circuit on aerosol deposition in pediatric patients receiving noninvasive ventilation, 
and one in vitro/in vivo study, Fauroux et al. (2000), was planned to assess differences in aerosol 
delivery with and without noninvasive ventilation. Nonetheless, there is insufficient objective 
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information to the guide physician while choosing the best device for aerosol drug delivery in 
children who receive noninvasive ventilation. It would be difficult to extrapolate from the results 
of adult noninvasive ventilation aerosol studies and to utilize in the pediatric patient. Children 
have smaller tidal volumes, higher respiratory rate, lower inspiratory/expiratory ratios, and 
smaller airways than adults. Earlier studies have recommended that these elements in infants and 
small children give to lower inhaled drug delivery than in adults (Schüepp KG, Straub D, 
Mo¨ller A, Wildhaber JH, 2004) 
 The major discovery of the recent study was that the type of nebulizers and masks had an 
impact on aerosol drug delivery to this simulated passive pediatric lung model receiving 
noninvasive ventilation.  
 
Impact of Nebulizer Type 
 The vibrating-mesh nebulizer delivered more aerosol drug than the jet nebulizer, in all 
conditions examined. This study found that VMN is 2-3 fold more efficient than JN. This result 
agrees with the findings of Galindo-Filho et al. (2015), who evaluated mesh and jet nebulizers 
during noninvasive ventilation by using radio-aerosol pulmonary index and radio-aerosol mass in 
pulmonary compartments settings in vivo study. They assess radio-aerosol by using the gamma 
camera. They found that drug delivery with VMN was more than 2-fold greater than JN in 
healthy subjects. However, the inhaled mass percent of the JN and the VMN in their research 
was higher than this study. This variance is predictable due to the population examined in this 
study (pediatrics population) compared to the adult population in their study. Ari, A., de 
Andrade, A. D., Sheard, M., AlHamad, B., & Fink, J. B. (2015) reported that the aerosol 
collection with adult lung model was larger than a pediatric model, regardless of the nebulizer 
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device type (JN and MN) (p<0.05). Additionally, aerosol deposition was significantly larger in 
an adult lung model than the infant lung model used with JN (p=0.001 and p=0.002, 
respectively) and MN (p=0.001 and p=0.005, respectively).  
 
Impact of Interface Type 
 The mouthpiece, nasal pillows, nasal mask, oronasal mask, total facemask, and helmet 
are often utilized with noninvasive ventilation. Although the choice of masks is depended on the 
pediatric patient tolerance and facial skin breakdown, it is essential to notice that certain 
interfaces (the total facemask and helmet mask) are not suitable for aerosol drug therapy through 
noninvasive ventilation because of patient contact to aerosol drug and flow from the noninvasive 
ventilation (Hess DR, 2005). While aerosolized medications are produced to patients getting 
noninvasive ventilation, therapist must consider leaks of the aerosol drug into the eyes of the 
patient (Kelly JT, Asgharian B, Kimbell JS, and Wong B, 2004). 
 There are limited studies that examine the clinical efficiency of the interfaces on pediatric 
receiving NIV.  In this study, we exam the standard oronasal mask, the oronasal mask with nose 
cushion, and the nasal mask. These interfaces are used with pediatric patients who receive NIV. 
Regardless of the nebulizer device type, both oronasal masks were more efficient than the nasal 
mask by 15–20 fold. The results were expected and depended on the expected nasal deposition of 
aerosol droplets 2 to 7 µm in size, 40 to 99% of the aerosol inhaled during noninvasive 
ventilation is similarly to deposit in the nose. (Chen YS, 2003 and Kelly JT, Asgharian B, 
Kimbell JS, and Wong B, 2004). Aerosol deposition in nasal passages significantly reduces drug 
delivery to the lung, and could reduce bronchodilator efficacy compared to inhalation with an 
oronasal. 
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 When the standard oronasal mask is compared to the oronasal mask with nose cushion, 
this study found that the standard oronasal mask was more efficient than the oronasal mask with 
nose cushion with either type of nebulizer. Differences in the amount between the standard 
oronasal mask and the oronasal mask with nose cushion could be the characteristics of the 
interface. The presence of the nose cushion will disturb the way the aerosol may effect and 
disturb the deposition of inhaled aerosols drugs in the filter. 
 
Impact of Delivery Technique 
 The delivery of aerosolized medication is affected by the type of aerosol device and 
masks used during noninvasive ventilation, the place of the leak port, and the location of the 
aerosol device in the circuit (Chatmongkolchart S, Schettino G, Dillman C, Kacmarek R, and 
Hess D. 2002, Branconnier M, and Hess D.2005).  Bi-level ventilators consume either a mask or 
a single limb circuit with a leak port that works similar a passive exhalation port from the patient. 
The position of the leak port is essential for aerosol therapy during noninvasive ventilation , as it 
promotes the loss of aerosol to the environment; therefore, regardless of the type of aerosol 
device used during NIV, putting the interfaces before the leak port increases aerosol delivery 
during noninvasive ventilation (Michotte and colleagues (2014), Abdelrahim (2010), 
Branconnier et al (2005), and Dai et al (2014)). Previous studies reported that aerosol deposition 
during NIV will be influenced by the NIV settings.  The aerosol delivery will be decreased when 
increasing the expiratory pressure, while an increase in aerosol deposition in patients receiving 
NIV was seen when increasing the inspiratory pressure. Therefore, an aerosol device located 
between the leak port and facemask could produce up to 25% of the nominal dose to the patient 
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operating on high inspiratory and low expiratory pressure settings during NIV 
(Chatmongkolchart at el. 2002). 
 
Limitations 
  The results of this study must not be widespread to the varied range of respiratory 
parameters representing different age ranges of pediatrics because this study used one set of 
respiratory patterns. While it is well recognized that pediatric patients mostly have highly 
unpredictable respiratory patterns when awake, which influences deposition, and this is more 
worsened by their intolerance of the interface. Simulating such variations in respiratory 
parameter or the failure to tolerate a carefully fitting interface was outside the possibility of this 
study. Since the study model delivers a very regular flow, volume, and frequency during aerosol 
treatment, the results of this study could overvalue aerosol drug delivery in vivo.  Also, results of 
aerosol medication using these models has limited success because of less aerosol to airway due 
to effect of oral cavity.  
 
Clinical Implications 
 Physicians frequently request the efficiency of nebulizers that are utilized with various 
masks. In this study, we compared the use of jet nebulizer and mesh nebulizer with three types of 
masks in pediatrics receiving NIV. The statistics showed that mesh nebulizer was superior to jet 
nebulizer in positions of aerosol drug delivery, and aerosol deposition taken with the standard 
oronasal mask was greatest, regardless of the aerosol device examined in this study.  
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Suggestions for Future Research 
 Further studies are required in medical situations to control the clinical efficiency of 
aerosol treatments with higher doses and their effect on a patient’s care, consequences, and 
source operation. Different breathing patterns must be tested to control how aerosol deposition 
would be influenced by different diseases and patient situations. In future research, the use of the 
V-60 NIV is suggested due to the prevalence of the device in acute health care.  
 
 
Conclusion 
Delivery efficiency in a simulated pediatric lung model receiving NIV was influenced by the 
style of aerosol device and masks used for aerosol therapy. Aerosol drug delivery was greatest 
with the standard oronasal mask with both jet and mesh nebulizers, while the nasal mask was 
least effective in these simulated pediatric lung model receiving NIV. Delivery effectiveness of 
jet nebulizer was less than mesh nebulizer in all conditions examined in this study.  
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